Hema Now: Myeloma, CAR-T, and Emerging Immunotherapies - European Medical Journal

Hema Now: Episode 18: Myeloma Genetics, CAR-T, and Emerging Immunotherapies

Hematology

Hema Now | Episode 17

In this episode of Hema Now, host Jonathan Sackier is joined by Rafael Fonseca, Consultant at the Division of Hematology/Oncology at the Mayo Clinic. Together, they delve into the biology, diagnosis, and evolving management of multiple myeloma and related plasma cell disorders. Their conversation addresses common misunderstandings about myeloma, differentiates between its various forms and stages, and highlights Fonseca’s pioneering research. 

 

Apple | Amazon Music | YouTube | Download MP3 (29 mins)

Speaker bio: 

Rafael Fonesca

Rafael Fonseca

Rafael Fonseca is a distinguished Haematologist at Mayo Clinic, specialising in multiple myeloma and related plasma cell disorders. He earned his medical degree at Universidad Anáhuac in Mexico, and went on to complete his residency in Internal Medicine at the University of Miami, Florida, USA followed by a Hematology and Oncology fellowship at Mayo Clinic in Rochester, Minnesota. 

Timestamps:     

01:44 – Quickfire questions 

07:25 – CAR-T cell therapy 

10:48 – Anti-CD38 antibodies 

13:31 – Minimal residual disease 

14:30 – Bispecific antibodies 

15:31 – Antibody-drug conjugates 

19:04 – ASCO 2025 

21:24 – Genetic discoveries 

26:28 – Fonseca’s three wishes 

 

The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.